A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

NCT05083078 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped The study was stopped due to unanticipated feasibility constraints.

Conditions

Arthritis, Psoriatic
Healthy

Interventions

DRUG: Guselkumab
DRUG: Risankizumab

Sponsor

Janssen Research & Development, LLC